

## Index

- Abbott Laboratories, 482  
 AbbVie, 213–14, 482  
 Abele, John, 175  
 Abelson virus, 344–45, 355  
 Abelson, Herb, 342, 344  
 Abgenix, 365  
 accelerated approval status  
   FDA designation, 22  
 ACE inhibitors  
   captopril (Capoten), 126, 140  
   captopril (Capoten), approval of, 155  
   enalapril, 155  
   enalaprilat, 155  
   general, 119, 135  
   lisonopril, 155  
   Monopril, 285  
   perindopril, 155  
   ramipril, 126, 155  
 Acemoglu, Daron, 55  
 acquired immune deficiency syndrome  
   (AIDS), 55, 203  
   research on, 12  
 Acthar, 65n. 7  
 acute lymphoblastic leukemia (ALL), 419  
 adenylate kinase, 291  
 Advanced Cardiovascular Systems (ACS), 187  
 age-related macular degeneration (AMD), 377,  
   380–81, 401, 403  
 Aggertal Clinic, Engelskirchen, 172, 181  
 agricultural firms  
   Monsanto, 8, 482  
 Al-Azkhora (*The Therapy*), 127  
 Albert Einstein College of Medicine  
   (AECM), 83  
 Alberts, Alfred, 92  
 aldosterone, 121  
 Allen, Duff, 165  
 Alliance for Cancer Gene Therapy  
   (ACGT), 447  
 Alt, Fred, 365, 386  
 Alzheimer, Alois, 227, 229, 242  
 Alzheimer's Association, 230  
 Alzheimer's disease, 55, 364, 503, 518  
   amyloid plaques, 228  
   cause, 51  
   contrasted with dementia, dementia with  
     Lewy bodies, 223  
   drugs under development, 245  
   early drug development, 230  
   early prediction, 251  
   early-onset, 232  
   general, 223  
   inflammatory therapies, 246  
   link with Down syndrome, 232  
   sporadic, 234  
   statistics, US, 224  
   tau hypothesis, 242, 245  
 American Board of Medical Specialties, 305  
 American College of Medical Genetics (now  
   American College of Medical Genetics  
   and Genomics (ACMG)), 305  
 American College of Medical Genetics and  
   Genomics (ACMG), 305  
 American Heart Association (AHA), 75, 175  
 American Home Products, 482  
 American Philosophical Society, 455  
 American Research and Development  
   Corporation, 482  
 American Society for Hypertension  
   Robert Tigerstedt Distinguished Scientist  
   Award, 130  
 American Society of Clinical Oncology, 379

- American Society of Hematology (ASH), 439  
 Amgen, 368–69, 371–72, 377, 393, 465, 482  
 AMP-activated protein kinase (AMPK),  
   289–92, 298  
 Amylin Pharmaceuticals, 486  
 amyloid cascade hypothesis, 235, 235n. 33,  
   237f. 8.1, 244–45, 245n. 62  
 amyloid precursor protein (APP), 232  
 amyotrophic lateral sclerosis (ALS), Lou  
   Gehrig's disease, 55, 364  
   cause, 51  
 Anadys Pharmaceuticals, 208  
 anaphylactic shock, 137  
 Anatomical Therapeutic Chemical (ATC)  
   Classification System code  
   World Health Organization, 22  
 Anderson, Robert, 278  
 Angell, Marcia, 13, 497  
 Angiologische Klinik – Max Ratschow Klinik,  
   Darmstadt, 171  
 angiotensin  
   angiotensin I and II, 121  
 angiotensin converting enzyme, ACE, 121  
 angiotensin II  
   use of saline instead of water, 135  
 angiotonin, 134  
   angiotonin-activator, 134  
 Ann Arbor, Michigan, 102  
 Anthem, 215  
 antibiotics, 18  
 anti-depressants  
   pricing, 63  
 antidiuretic hormone, ADH (vasopressin),  
   122f. 5.1  
 antihypertensives, 231  
   Aceon, 125t. 5.1  
   Altace, 125t. 5.1  
   Bumex, 125t. 5.1  
   Calan SR, 125t. 5.1  
   Capoten, 125t. 5.1  
   Cardizem, 125t. 5.1  
   Corgard, 125t. 5.1  
   Diuril, 125t. 5.1  
   Esidrix, 125t. 5.1  
   Indera, 125t. 5.1  
   Lasix, 125t. 5.1  
   Lopressor, 125t. 5.1  
   Lotensin, 125t. 5.1  
   Lotrel, 125t. 5.1  
   Lozol, 125t. 5.1  
   Mavik, 125t. 5.1  
   Midamar, 125t. 5.1  
   Norvasc, 125t. 5.1  
   Prinivil, 125t. 5.1  
   Procardia, 125t. 5.1  
   Sectral, 125t. 5.1  
   Tenormin, 125t. 5.1  
   Thalitone, 125t. 5.1  
   Toprol XL, 125t. 5.1  
   Vasotec, 125t. 5.1  
   Visken, 125t. 5.1  
 APOE4, 233, 237f. 8.1, 239  
 Apple, 463  
 Arcalyst, 375  
 Aricept, 231  
 Aron Laboratories, 280  
 Arrhenius, C.J., 149  
 Arthur, Brian, 520  
*Aspergillus terreus*, 92  
 AstraZeneca, 482  
   Paludrine, 278  
 atherosclerosis, 77  
   initiation and progression, 77  
 Atomic Energy Commission, US, 520  
 atorvastatin, 155  
 Auguste D  
   Alzheimer's patient, 227  
 autoimmune diseases  
   drug pricing, 63  
 Avastin  
   angiogenesis, 399  
   compared with Lucentis, 405  
   general, 398  
   mechanism of action, 402  
 Aventis, 379  
 bacteria  
   discovery of, 2  
 Baikie, A.G., 337  
 Bain & Company, 394  
 Bakhle, Y.S. (Mick), 137  
 balloon angioplasty  
   description, 160  
 Baltimore, David, 341, 345–46  
 Banting, Frederick, 275, 516  
 Barber, Bernard, 520  
 Bateson, William, 304  
 Baumert, Thomas, 217  
 Baxter, 482, 487  
 Baycol, 107  
 Bayer, 107, 369, 381, 394  
 Bayh/Dole Act, 1980, 11, 54

- BCR-ABL* gene fusion, 333, 344  
 Bcr-Abl protein kinase, 346f. 11.2  
 Beck, Claude, 165  
 Beechams Pharmaceuticals, 90, 109  
 Bell Laboratories, 463, 465, 523  
 Bell, James, 283  
 Bennett, John Hughes, 334  
 Bergman, Per, 129  
 Berman, Leonard, 147  
 Best, Charles, 275, 517  
 beta blockers, 125  
 Bethesda Naval Hospital, 119  
 bevacizumab, 398  
 Beyond the Shadow of a Drought  
   report, 19  
 Big Ag, 8, 451  
 Big Pharma, 5, 8–9, 362, 381, 451  
 big-C scientific creativity  
   definition, 457  
 biguanides, viii, ix, 262, 263f. 9.1, 268, 269t.  
   9.1, 277–78, 280, 282–83, 287, 288n. 87,  
   289f. 9.4, 291, 293–94, 298–99  
 Bilheimer, David, 95  
 Biogen, 252, 260, 393–94, 477, 482, 484, 487  
 biologics, 7, 21, 25, 29, 54  
 Biologics License Applications (BLAs)  
   definition, 21  
 biotech, 7  
   small, 9  
 biotechnology companies  
   Abgenix, 365  
   Amgen, 368–69, 371–72, 377, 393, 465  
   Baxter, 482, 487  
   Biogen, 260, 393–94, 477, 482, 484, 487  
   Biogen, Alzheimer's drug research, 252  
   Celera Genomics, 329, 524  
   Chiron Corporation, 193, 198, 218  
   fully integrated biopharmaceutical  
   companies (FIBCOs), 362  
   Gen-Probe, 487  
   Genentech, 368, 378–79, 381–82, 391, 395,  
   403, 405  
   Genentech University, 405  
   Genentech, Herceptin, 403  
   Genzyme, 477, 482  
   geographic clusters, 477  
   Hybritech, 487  
   Illumina, 486  
   Inhibitex, 208  
   Intermune, Infergen, 203  
   Juno Therapeutics, 433  
   Kinetix Pharmaceuticals, 352  
   Kite Pharma, 433  
   Life Technologies, 486  
   Medarex, 365  
   mergers and acquisitions, 467  
   Regeneron, 463  
   Regeneron, Arcalyst, 375  
   Regeneron, Eylea, 375  
   Regeneron, Lucentis, 380  
   Regeneron, name origin, 374  
   Regeneron, Orphan Receptor initiative, 374  
   Regeneron, Praluent, 387  
   Regeneron, Regeneron 5, 392  
   Regeneron, Taxotere, 379  
   Regeneron, TRAP technology, 375  
   Regeneron, VelociGene technology, 368, 382  
   Regeneron, VelociSuite technologies, 384  
   Regeneron, Zaltrap, 375  
   resilience as a factor of success, 362  
   technological innovations, 467  
   Vertex, 205  
 biotechnology companies, mergers and  
   acquisitions, 500  
 biproduct inhibitor, vii  
 Birndorf, Howard, 487  
 Bishop, Michael, 343  
 Black, Donald, 104  
 Blair, Henry, 477  
 Bloch, Konrad, 83  
 blood pressure drugs  
   pricing, 63  
 Blumberg, Baruch  
   hepatitis B screening test, 193  
 Bock, Lazlo, 111  
 Bodmer, Walter, 345  
 Bohr Model, 53  
 Bohr, Niels, 53, 327  
 Bokelman, Delwin, 111  
 Boston Consulting Group, 481  
 Boston, Massachusetts, 85  
 Boveri, Theodor, 335  
 Boyer, Herbert, 477  
 Bradley, Daniel W., 193  
 bradykinin, 136  
 bradykinin potentiating factors (BPFs), 137  
 Braun-Menéndez, Eduardo  
   renin, 132  
 breakthrough drug status  
   FDA definition, 22  
 breast cancer  
   hereditary, 326

- Brentjens, Renier, 424, 436, 446  
 Brierley, J.B., 229  
 Bright, Richard, 127, 146  
 Bristol-Myers Squibb (BMS), 103, 106, 208,  
 213, 215, 219, 285  
   Squibb Institute for Medical Research, 138  
 British National Formulary, 281  
 Brookhaven National Laboratory, 138  
 Brown, Michael, 95–98, 113–14, 364  
 Brown-Séguard, Charles Edouard, 128  
 Bruenn, Howard, 119  
 Buchdunger, Elizabeth, 349, 355  
 buformin, 263f. 9.1, 270t. 9.1, 282–83, 294  
 Bumpus, Merlin, 135  
 Burn, J. Harold, 151  
 Bush, George W., 54  
 Byers, Larry, 142
- California Institute for Regenerative  
 Medicine, 486  
 Cambridge Innovation Center, 484  
 Cambridge, Massachusetts  
   biotech cluster, 481  
 Campana, Dario, 429  
 Canaani, Eli, 345  
 Canadian Diabetic Association (CDA), 283  
 cancer, 1  
   chemotherapy, 18  
   mortality, 18  
   Philadelphia chromosome-positive chronic  
   myelogenous leukemia, 63  
   treatment overview, 418  
   US statistics, 441  
 Cancer Research Institute, 404  
 Cape Province, South Africa, 104  
 captopril  
   ACE inhibitor, 126, 140  
 captopril, ACE inhibitor  
   approval of, 155  
 CAR T-cell therapy, 417  
 CAR T-cells  
   manufacture and administration, 424  
 carboxypeptidase A, 142  
 cardiovascular disease (CVD)  
   development of statins, 75  
   role of cholesterol, 79  
   root cause, atherosclerosis, 77  
 Case Western Reserve University, 131  
 Caspersson, Torbjörn, 339  
 Celera Genomics, 329, 524  
 Centers for Disease Control & Prevention, US  
 (CDC), 193, 198  
 Chain, Ernst Boris, 16  
 chance and serendipity, xii, 146, 152, 154–55,  
 159, 179–80, 363, 379, 395, 458–59, 468,  
 504  
   double serendipity, 338  
   Horace Walpole, 458  
   role in scientific discovery, 152  
 Chaveau, Jean-Baptiste Auguste  
   double lumen catheter, 164  
 Chemical Development, 102  
 Chen, K.K., 278  
 Children's Hospital of Philadelphia, 417, 432  
 chimeric antigen receptor (CARs), 417  
 Chiron Corporation, 193, 198, 218  
 cholesterol  
   biosynthetic pathway, 86, 117  
   end-product inhibition, 85  
   HMG-CoA reductase, 86  
   role in cardiovascular disease, 79  
 chronic lymphocytic leukemia (CLL), 419  
   use of CAR-T therapy, 417  
 chronic myelogenous (or myeloid)  
 leukemia (CML)  
   description, 331  
   use of imatinib in treatment, 311  
   use of imatinib, 316  
 Chung, Raymond, 217  
 Ciba-Geigy, 284, 333, 347, 349–52, 355, 357,  
 359  
 Ciba-Geigy, protein kinase inhibitors, 347  
 CIBE, 92  
 Cleveland Clinic, 135, 167–68  
 Cohen, Barry  
   Merck, 94  
 Cohen, Stanley, 477  
 Collett, Marc, 344  
 Collins, Francis, 250  
 Collip, James Bertram, 275  
 Columbia University, 365  
 Community Health Initiative, 319  
 Conquest of Cancer Act, 340, 356–57  
 consumers' surplus, economic term, 48  
 Cook Group, 186  
 Cook, William  
   The Cook Company, 169  
 Copernicus, 518  
 Cordes, Eugene, 111  
 Cornell University, 364  
 coronary artery bypass with graft (CABG)  
   surgery, 161  
 coronary artery heart disease, 120  
 Corsellis J.A.N., 229  
 creative people  
   personality traits, 453

- Cresswell, Ronnie  
 Parke-Davis Research, 103  
 Creutzfeldt-Jakob (mad cow) disease, 223  
 Cri du Chat syndrome, 337  
 crizotinib, 312  
 Cruzan, Susan M., 284  
 Curd, F.H.S., 277  
 CURVES study, 106  
 Cushman, David, 139, 152  
 Custer, Philip, 338  
 Cutler, Elliott, 165  
 CVS, 215  
 cyclic AMP (cAMP), 292  
 cystic fibrosis, 68  
 cytokine interleukin-1 (IL-1), viii, 246, 375, 378f. 12.1  
 cytokine storm, 431  
 Czechoslovak Radiologic Congress, 170
- Daiichi Sankyo, 82  
 Daklinza, 215  
 Daley, George Q., 346  
 Dallas, TX, 95–96  
 Dana-Farber Cancer Institute, 347, 350  
 Darwin, Charles, 457  
 Davis, Jefferson, 474  
 Davis, Sam, 375  
 de Geus, Arie, 474  
*De Humani Corporis Fabrica*, 14  
 Dechiara, Tom, 366  
 Department of Agriculture, US, 481  
 Department of Energy, US, 481  
 Department of National Health and Welfare, Canada, 283  
 Department of Veterans Affairs, US, 213  
 diabetes, 18  
 cause, 52  
 diabetes, type 2  
 compared with diabetes, type 1, 264  
 discovery of insulin, 275  
 drugs, history, sulfonyleureas, 268  
 metformin, 262  
 statistics, 266  
 Synthalin, 274  
 Digital Equipment, 482  
 diguanides, ix, 263f. 9.1, 269t. 9.1, 279, 294  
 direct acting antivirals (DAAs)  
 boceprevir (Victrelis), 205  
 overview, 205  
 teleprevir (Incivek), 205  
 Discovery Chemistry, 102  
 discovery hubs  
 Asia, 522  
 discovery in the life sciences  
 economic model, 5  
 effect of price discrimination, 402  
 funding decisions, 43  
 high costs of R&D, 491  
 improvements in agriculture and health, 2  
 late 1990's changes, 11  
 management issues, 449  
 organizational form and influence, 5  
 role of government, 491  
 role of the team/group, 461  
 role of unintentional findings, 460  
 summary of history, 14  
 theories and ideas about, 5  
 theories for falloff in new discoveries, 10  
 theories of causes, 519  
 Dotter, Charles, 161, 168  
 Dotterization, Dottering, 170  
 double helix, 55  
 Down syndrome, 337  
 cause, 308  
 Down, John Langdon, 305  
 Drachman, David, 230  
 Drucker, Brian, 347, 350, 359  
 drug development, new  
 average cost calculation, 31  
 cost estimates - cash versus capitalized, 32  
 costs, 29  
 economic theories, 52  
 history, 19  
 history, 1990s, 53  
 tax benefits, 33  
 drug prices  
 not related to R&D costs, 70  
 drug pricing  
 price discrimination, 402  
 Duckworth, Angela  
 concept of "Grit", 361  
 Dupilumab, 387  
 Duval, Denise, 280
- Eastman Kodak, 167  
 Ebola virus, 195, 387  
 Economides, Aris, 375  
 Einstein, Albert, 457  
 Elan Pharmaceuticals, 240  
 Eli Lilly, 187, 238, 251, 486  
 Eli Lilly & Company Biological Laboratories, 276  
 Eli Lilly Research Laboratories, 132  
 Emanuel, Ezekiel, 498  
 Emory University, 187  
 Emperor Charles II, 14

- enalapril, ACE inhibitor, 155  
 enalaprilat, ACE inhibitor, 155  
 Endo, Akira, 75, 115, 396  
   Compactin Development Project, 1976, 89  
   history, 82  
   Lasker ~DeBakey Clinical Medical Research  
     Award, 2008, 85  
 Erikson, Ray, 344  
 Eroom's Law, 19  
 Eshhar, Zelig, 426, 446  
 European Medical Agency (EMA), 441  
 exome sequences, 319–20  
 Express Scripts, 215  
 Eylea, 362, 375
- Fagan, Violet M., 84  
 familial hypercholesterolemia (FH), 323  
 Fandl, Jim, 366  
 Farbwerke Hoechst, 276  
 Fasciolo, Juan  
   renin, 132  
 fast track approval, 104  
 Favaloro, Rene  
   first coronary artery bypass with graft  
     (CABG), 168  
 Feldberg, Wilhelm, 137  
 Ferrara, Napoleone, 404, 415  
 Ferreira, Sérgio, 137  
 financing discovery  
   economic model, 6  
   introduction to issues, 6  
 first in class drugs  
   ATC category, 22, 25, 28  
 Fleming, Alexander, 75, 179  
   connection to Akira Endo's work, 86  
   discovery of penicillin, 512  
   discovery of penicillin. *See* penicillin  
 Flemming, Walther, 335  
 Florey, Howard Walter, 16  
 Fogarty, Thomas, 171  
 Food and Drug Administration (FDA), US,  
   207, 387, 409, 433, 441  
   accelerated approval status, 22  
   Alzheimer's treatments, 253  
   Avastin, 398  
   biologics license applications (BLAs), 362  
   biotech firms, NCEs and NBEs, 466  
   breakthrough drug designation, 22  
   drug approval methods, 11  
   drug review designations, 22  
   fast track approval, 104  
   lack of attention to profits, 493  
   Orphan Drug Act, 24  
   Orphan drug designation, 22, 29, 33  
   Poisonous Plant Database, 298  
   policies, 46  
   Priority Review status, 22  
   Safety and Innovation Act (FDASIA), 209  
 Forssman, Werner, 165  
*Fortune* magazine, 106  
 Fovea Pharmaceuticals, 380  
 Fox Chase Cancer Center, Philadelphia, 338  
 Framingham Heart Study, 85, 113, 117  
 Framingham, Massachusetts, 85  
 Frank, Erich, 273  
 Fred Hutchinson Cancer Research Center,  
   Seattle, 433  
 French Academy of Sciences, 511  
 frontotemporal dementia, 223–24, 243f. 8.2,  
   246
- G7 countries  
   NME approvals, 29  
 galegine, 269t. 9.1  
 Galen, 14, 505  
 Garcia, Eusebio, 278  
 Garrod, Sir Archibald  
   Croonian Lectures, 305  
 gastrointestinal stromal tumor (GIST), 312  
 Gattex, 66  
 Geisinger, 329, 392  
 Geisinger GenomeFIRST™, 321f. 10.4  
 Geisinger Health System (GHS), 317  
 Genentech, 368, 378–79, 381–82, 391, 393,  
   395, 402–03, 405  
   Herceptin, 403  
 Genentech University, 405  
 General Practice Research Database, UK, 126  
 generic drugs  
   investment in, 51  
   new, 21  
 genetic revolution, 55  
 genetics  
   definition, 301  
 genomic medicine  
   GenomeFIRST™ approach, 320  
   Phenome First approach, 306  
   value of, 315  
 genomics  
   definition, 301  
 Gen-Probe, 487  
 Genzyme, 477, 482  
 Gianturco, Cesar, 187  
 Gilbert, Walter, 477

- Gilead, 208, 213, 220  
 Gilman, Alfred, 364, 369  
 Glasgow Blood Pressure Clinic, 126  
 GlaxoSmithKline, 64, 90, 469  
   Centers of Excellence for Drug Discovery (CEDD), 495  
 Gleevec (imatinib), 418  
   2-phenylaminopyrimidine, 349  
   introduction, 331  
 glucagon, 289f. 9.4, 290f. 9.5, 292  
 gluconeogenesis  
   inhibition, 268, 286, 291, 293  
 Goat's rue, *Galega officinalis*, 270  
 Goldberg, Murray, 369  
 Goldblatt, Harry, 135, 147  
   kidney clamp, 131  
 Goldstein, Jim, 114  
 Goldstein, Joseph, 95–98, 113, 364  
 Golgi, Camillo, 228  
 Google, 111  
 Graham, Evarts, 165  
 Grant, Ulysses, 475  
 Green, Ted, 487  
 Greene, Lewis, 138  
 Greenfield, Indiana, 276  
 Grove, Andy, 473  
 Grüntzig, Andreas, 161, 170–71, 462  
 Grüntzig, Michaela, 173  
 Grundy, Scott, 95  
 Guidant Corporation, 187  
 Guy's Hospital, 127  
*Guys Hospital Report*, 128
- HAART (highly active anti-viral therapy), 206  
 Hagedorn, Hans Christian, 276  
 hairy cell leukemia, 203  
 Hales, Stephen, 164  
 Hanna, Elias, 176  
 Hanseman-Boveri hypothesis, 335  
 Hardy, John, 235  
 Harvard University, 426, 477–78, 485  
 Harvey, William, 127, 516  
 Hasse, H.M.  
   opposition to use of catheters, 172  
 HCV  
   infectious cycle, 196  
 HCV drug development  
   timeline, 207  
 HCV genome  
   organization, 195  
 Healthcare Common Procedure Coding System (HCPCS), 380
- heart disease, 1  
   cardiac catheterization, 163  
   types of medical devices, 163  
 heart failure, 120  
 Heart Protection Study (HPS), UK, 113  
 hepatitis A virus (HAV)  
   compared to HBV and HCV, 193  
 hepatitis B virus (HBV)  
   compared to hepatitis C virus (HCV), 193  
 hepatitis C  
   drug pricing, 63  
   Sovaldi, 58  
 hepatitis C virus (HCV), 187  
   Daklinza, 213, 215  
   direct acting antivirals (DAAs), 205  
   drug discoveries, 204  
   drug pricing, 211  
   Eplclusa, 213  
   growth in drug sales, 207  
   hepatitis C, cirrhosis, liver cancer, 191  
   highly active anti-viral therapy (HAART), 206  
   latest drugs, 213  
   ledipasvir (Harvoni), 211  
   lost productivity, US workforce, 192  
   Olysio, 213  
   sofosbuvir (Sovaldi), 209  
   Viekira Pak, 213–14  
   Viekira XR, 213  
   worldwide infection statistics, 191  
   Zepatier, 213, 215  
 Herceptin, 403  
 heterozygous familial hypercholesterolemia (FH), 90  
 Higgins, Gerald, 235  
 high blood pressure  
   drug development, 57  
 high cholesterol  
   drug development, 57  
 high density lipoproteins, HDLs, 81  
 Himsworth, Harold, 266  
 Hippocrates, 127, 302, 304  
 Hitotsubashi University, Japan  
   Institute of Innovation Research, 459  
 HMG-CoA reductase, 86  
 Hoechst AG, 482  
 Holland, Michigan, 102  
 Hollunger, Gunnar, 287  
 Hooke, Robert, 516  
 Hopff, Heinrich, 173  
 Hôpital de la Pitié, Paris, 280  
 Horecker, Bernard, 109

534

*Index*

Horovitz, Zola, 141  
 Houghton, Michael, 193  
 Houssay, Bernardo A.  
   renin, 132  
 Hsu, T.C., 336  
 Huebner, Robert J., 343  
 Human Genome Project (HGP), 309, 319  
 human genome, mapping, 56  
 human papillomavirus (HPV), 203  
 humanized monoclonal  
   antibodies, 405–06, 415  
 Hungerford, David, 334, 338  
 Hunter, John, 163  
 Hunter, Tony, 344  
 hybridization and selective breeding, 2  
 Hybritech, 487  
 hypercholesterolemia  
   Praluent, 387  
 hyperglycemia, 265  
 hypertension, 119  
   statistics, US, 120  
 Icahn School of Medicine, Mt. Sinai, 201  
 Icahn, Carl, 394  
 idea  
   definition of, 56  
 Idec Pharmaceuticals, 487  
 Illingworth, Roger, 95, 104  
 Illumina, 486  
 imatinib, 316  
   treatment for CML, 311  
 Imhotep  
   Edwin Smith Surgical Papyrus, 127  
 immunotherapy  
   drugs, Humira, Embrel, Avastin, Lucentis, 240  
 Imperial Chemical Industries Ltd., 277  
 infectious disease, 2  
 influenza epidemic, 2  
 Institut Pasteur, 15  
 Institute for Clinical and Economic Review  
   (ICER), 499  
 Institute of Biology, São Paulo, Brazil, 136  
 Institute of Medicine, 327  
 insulin  
   discovery, 275  
 Intel, 473  
 intellectual property  
   disputes, 13  
 interferons  
   drawbacks to treatment, 202  
   general, 202  
   interferon alpha, 202

Intermune, 203  
 intuitive medicine  
   definition, 304  
 investment  
   conceptual model of investing, 43  
   decision-making, 47  
   fundamental equation, 44  
   net revenue, 44  
   probability that product will come to  
   market, 44  
 Jacobs, Patricia, 337  
 Jenner, Edward  
   Jennerian Society, 15, 509  
   smallpox vaccine, 508  
 Jobs, Steve, 455  
 Johnson & Johnson, 205, 213, 482, 486  
 Johnson, Steven, 522  
 Joslin, Eliot P., 276  
 Judkins, Melvin, 168, 170  
 June, Carl, 427, 436, 445  
 Juno Therapeutics, 433  
 JUPITER study, 108  
 Kahn, Joseph R., 135  
 Kalydeco, 68  
 Kanazawa University School  
   of Medicine, Ishikawa,  
   Japan, 96  
 Kanter, Rosabeth Moss, 449, 489  
 Kaposi's sarcoma, 203  
 Karlovy Vary (Karlsbad), 170  
 Karolinska Institute, 129, 167  
 Katzman, Robert, 230  
 Kayali, Zeid, 211  
 Kellaway, Charles Halliley, 137  
 Kenexa, 367  
 Kidd, Michael, 229  
 kidney disease, 120  
 Kinetix Pharmaceuticals, 352  
 King Charles I, 516  
 King James I, 516  
 Kitano, Noritoshi, 88, 109, 117  
 Kite Pharma, 433  
 Klausner, Richard, 426  
 Kleiner Perkins, 487  
 Klinefelter's syndrome, 337  
 Koestler, Arthur, 457  
 Kornberg, Arthur, 364  
 Kraepelin, Emil, 227  
 Krogh, August, 276  
 Krogh, Marie, 276



- Kuhn, Thomas  
 paradigm shift, 3, 55, 517  
 Kuroda, Masao, 86  
 Kuwait, 107  
 kymograph  
 invention, 129
- La Jolla Institute, 485  
 La Jolla, California, 95  
 Lacquer, Ernst, 147  
 Lander, Eric, 308  
 Landsteiner, Karl, 303  
 Laragh, John, 141  
 LDL receptors, 98n. 50  
 LDL receptors (LDLRs), 90, 97–98, 112, 388  
 Leavitt, Janet, 230  
 ledipasvir, 211  
 Lee, Tim Berners, 484  
 Leloir, Luis. F.  
 renin, 133  
 Lescol, 106  
 Leu, Hans Jorg, 174  
 Levan, Albert, 337  
 Levine, Bruce, 427  
 Lichtlen, Paul, 185  
 Life Technologies, 486  
 Lilly Research Laboratories, 278  
 Lincoln, Abraham, 474  
 Lindblom, Charles, 474  
 Linn, Joshua, 55  
 Lipha Pharmaceuticals Co. Ltd, 285  
 Lipitor (atorvastatin), 101, 155  
 Lipobay, 107  
 Lipscomb, William, 142  
 lisinopril, ACE inhibitor, 155  
 little-C creativity  
 definition. *See* big C scientific creativity  
 London School of Economics, 137  
 London, UK, 127  
 lovastatin, 99, 117, 155  
 discovery, 93  
 low density lipoproteins, LDLs, 79  
 Lucentis, 380  
 compared with Avastin, 405  
 general, 398  
 Lucille P. Markey Charitable Trust, 365  
 Ludwig, Carl, 146  
 Lydon, Nicholas, 355  
 Lynch syndrome, 320
- Mabuchi, Hiroshi, 96  
 MacDonald, Lynn, 383  
 MacLeod, John, 275, 516  
 Macugen, 380  
 Malaria  
 treatments, Paludrine, 278  
 treatments, quinine, 277  
 Manhattan Project, 357  
 Martin, Daniel, 411  
 Martin, John, 209  
 Massachusetts Institute of Technology  
 (MIT), 478  
 Sloan School of Management, 484  
 Matter, Alex, 347, 355  
 Max Planck Institute of Biochemistry,  
 Martinsried, Germany, 406  
 Maximillian, Holy Roman Emperor, 506  
 McDonald, Jim, 111  
 McIntire, Ross T., 119  
 MD Anderson Cancer Center, University of  
 Texas, 352  
 me-too drugs  
 investment in, 51  
 new, 21  
 Medarex, 365  
 Medawar, Peter, 451  
 medical device companies  
 Advanced Cardiovascular Systems  
 (ACS), 187  
 Boston Scientific, 175  
 Cook Group, 186  
 Guidant Corporation, 187  
 Medi-Tech, 175  
 William Cook Europe, 178  
 medical devices  
 innovation, 160  
 medical genomics  
 definition, 301  
 Mehnert, Helmüt, 282  
 Memorial Sloan Kettering Cancer Center, 429,  
 432–33  
 Mendel, Gregor  
 Mendelian disorders, 302  
 Merck & Co., 91, 115, 130, 155, 205, 213, 215,  
 373, 396, 452, 486, 513  
 Woodruff, H. Boyd, 91  
 mergers and acquisitions  
 efforts to achieve economies of scale, size  
 efficiency, 9  
 Merrill Lynch Ventures, 369  
 metformin  
 effects on metabolism, 287  
 Mevacor (lovastatin), 93, 98, 103, 106, 155  
 mevalonate, 86

- mevastatin, 87  
 Mexico City, 521  
 Meyer, Thomas, 349  
 Milken Institute, 484  
 Milligan, John, 209  
 Milne, J.S., 337  
 Minkowski, Oscar, 274  
 Moloney virus, 344  
*Monascus ruber*, 93  
 Monsanto, 8, 482, 520  
 Moore, Gordon, 473  
 Morgan, Thomas Hunt, 336  
 Mukherjee, Siddhartha, 300, 405  
 Müller, Helmut, 273  
 Munich, Germany, 228  
 Muñoz, Juan M., 133  
 Murphy, Drew, 367, 382  
 MyCode® bio-repository (now Community Health Initiative), 319  
 Myler, Richard, 175, 177
- Nash, John, 453  
 National Academy of Sciences, 455  
 National Alzheimer's Project Act (NAPA), 255  
 National Cancer Act of 1971, 340, 357, *See* War on Cancer  
 National Cancer Institute (NCI), 341, 441  
 National Cardiovascular Center, Osaka, Japan, 89  
 National Eye Institute, 382, 410  
 National Heart, Lung and Blood Institute formerly National Heart Institute, 85  
 National Institute for Health and Clinical Excellence (NICE), UK, 297  
 National Institute of Allergy and Infectious Diseases, US, 193  
 National Institutes of Diabetes and Digestive and Kidney Diseases, US (NIDDK), 200  
 National Institutes of Health (NIH), US, 364, 382, 426, 428–29, 481, 502, 524  
 biomedical research funding, 18  
 Comparison of Age-Related Macular Degeneration Treatment Trial (CATT) trials, 410  
 funding for San Diego biotech cluster, 485  
 human genome mapping, 329  
 Institute of Translational Research (NCATS), 397  
 National Cancer Institute, 341  
 peer review, 29  
 research spending, 46  
 translational research, 8  
 National Science Foundation, US, 481  
 Naval Medical Research Institute, Bethesda, Maryland, 427, 445  
 NCATS. *See* National Center for Advanced and Translational Science  
 nephropathic cystinosis, 64  
 neurofibrillary tangles (NFTs), 228  
 New Molecular Entities (NMEs)  
 definition, 21  
 different types, 24  
 international approvals, 28  
 revenues, 26  
 New York Medical College, 154  
 New York, NY, 85, 106, 109  
 Newton, Isaac, 457  
 Newton, Roger, 102  
 Nobel Prize, 16  
 Howard Temin, 1966, 343  
 Phillip Sharp, 1993, 484  
 Nobel Prize in Physiology or Medicine  
 Alfred Gilman, 1994, 364  
 Arthur Kornberg, 1959, 364  
 Banting and McLeod, insulin, 276  
 Joseph Goldstein and Michael Brown, 1985, 364  
 Nobel Prize in Physiology or Medicine, 1985, 96  
 Nobel Prize, 1978  
 nomination of Grüntzig and Dotter, 178  
 Nordisk Insulinlaboratorium, 276  
 Novartis, 106, 219, 333, 352, 357, 369, 429, 486  
 Lucentis marketing rights, 409  
 Novartis-Penn Center for Advanced Cellular Therapeutics, Philadelphia, 433  
 Novo Terapeutisk Laboratorium (now Novo Nordisk), 276  
 Nowell, Peter, 334, 338, 354  
 Noyce, Robert, 473  
 NPS Pharma, 66
- Obama, Barack, 54  
 Olson, Doug, 417, 432, 445  
 Ondetti, Miguel, 139  
 Oregon Health and Science University, 104, 350, 404, 443  
 organizations  
 determining best types for innovation, 8  
 Orphan diseases  
 drug pricing, 63  
 treatment for, 58

- Orphan Drug Act, 24, 54, 494  
   tax credits, 33  
 Orphan drugs, 7  
   FDA designation, 22, 29, 33  
   Orphan Drug Act, 24, 54  
   Procysbi, 64  
 Osborn, Alex F., 462  
 ovarian cancer  
   hereditary, 326  
 Oxford University, 151, 521
- Page, Irvine, 147  
   renin, 132  
 Palmaz, Julio, 187  
 Paludrine  
   malaria treatment, 278  
 Papadopoulos, Nick, 367, 375  
 paradigm shift, 3, 55  
   definition, 457  
 Paris, France, 128  
 Parkinson's disease, 223, 248, 364  
 Pasteur, Louis, 508  
   chance, 154  
   discovery of bacterial infection, 10  
   Pasteur model, 53  
   pasteurization, 510  
 Patents  
   protected drugs, 59  
 Pauling, Linus, 457  
 PCOS (polycystic ovary syndrome)  
   treatment with metformin, 295  
 Peart, Stanley, 135  
 penicillin, 75  
*Penicillium citrinum*, 85  
 Penn AD Core Center (ADCC), 249  
 perindopril, ACE inhibitor, 155  
 peripheral vascular disease, 120  
 personalized medicine  
   definition, 302  
   Regeneron Genetics Center (RGC), 392  
 Pfizer, 8, 67, 105, 117, 469, 482, 486  
 Pharmaceutical companies  
   Abbott Laboratories, 482  
   AbbVie, 213, 482  
   Abbvie, Viekira Pak, 214  
   American Home Products, 482  
   Amgen, 482  
   Amylin Pharmaceuticals, 486  
   Anadys Pharmaceuticals, 208  
   Aron Laboratories, 280  
   AstraZeneca, 278, 482  
   Aventis, 379  
   Bayer, 107, 369, 381, 394  
   Beechams, 90, 109  
   BMS, Daklinza, 215  
   Bristol Myers, 106  
   Bristol-Myers Squibb, 103, 208, 213, 219, 285  
   Bristol-Myers-Squibb (BMS), Squibb  
     Institute for Medical Research, 138  
   Ciba-Geigy, 284, 333, 347, 349–52, 355, 357, 359  
   Ciba-Geigy, protein kinase inhibitors, 347  
   Daiichi Sankyo, 82  
   Elan Pharmaceuticals, 240  
   Eli Lilly, 187, 238, 486  
   Eli Lilly & Company Biological  
     Laboratories, Greenfield, Indiana, 276  
   Eli Lilly Research Laboratories, 132  
   Eli Lilly, Alzheimer's drug research, 251  
   Eli Lilly, Lilly Research Laboratories, 278  
   Farbwerke Hoechst, 276  
   Fovea Pharmaceuticals, 380  
   Genentech, Avastin, Lucentis, 402  
   Gilead, 208, 213, 220  
   Gilead, Sovaldi, 209  
   GlaxoSmithKline, 64, 90  
   GlaxoSmithKline, biotech-like units, 469  
   GlaxoSmithKline, Centers of Excellence for  
     Drug Discovery (CEDD), 495  
   Idec Pharmaceuticals, 487  
   Imperial Chemical Industries Ltd., 277  
   Johnson & Johnson, 205, 213, 482, 486  
   Kinetix Pharmaceuticals, 352  
   Lipha Pharmaceuticals Co. Ltd. (now owned  
     by Merck KGAA), 285  
   Lovartis, 106  
   Lucentis marketing rights, 409  
   Merck, 16, 91, 115, 130, 155, 205, 213, 373, 396, 452, 486, 513  
   Merck, H Boyd Woodruff, 91  
   Merck, P. Roy Vagelos, 91  
   Merck, Zepatier, 215  
   Nordisk Insulinlaboratorium, 276  
   Novartis, 219, 333, 352, 357, 369, 429, 486  
   Novartis, Gleevec, 333  
   Novartis-Penn Center for Advanced  
     Cellular Therapeutics, Philadelphia, 433  
   Novo Nordisk, 276  
   Novo Terapeutisk Laboratorium (now Novo  
     Nordisk), 276  
   NPS Pharma, 66

- Pharmaceutical companies (*cont.*)  
 Pfizer, 8, 67, 105, 117, 482, 486  
 Pharmasset, 208, 210, 219  
 Prizer, purchase of Warner-Lambert, 107  
 Questcor, 65n. 7  
 Raptor, 64  
 Regeneron, 362  
 Regeneron, Eylea, 362  
 Regeneron, Praluent, 363  
 Roche, 208, 391  
 Roche, Pegasys, 204  
 Roche, purchase of Anadys  
   Pharmaceuticals, 208  
 Roche, Roferon A, 203  
 Rona, Aron Laboratories, 281  
 Sandoz Pharmaceuticals, 102, 350, 352  
 Sandoz, fluvastatin, 110  
 Sankyo Research Laboratories, 85  
 Sanofi, 369, 379, 389, 394  
 Sanofi-Aventis, 276  
 Schering AG, Synthalin, 274  
 Schering-Plough, 205  
 Schering-Plough, Intron A, 203  
 Schering-Plough, Rebetrone, 204  
 Sumitomo, 369  
 Teva, 369  
 Vertex, 68  
 Warner-Lambert, 117  
 Warner-Lambert, Parke-Davis  
   Pharmaceutical Research, 100  
 Pharmaceutical companies, mergers and  
   acquisitions, 500  
   BMS purchase of Inhibitex, 208  
   Gilead purchase of Pharmasset, 208  
   Merck-Schering Plough, 389  
   Novartis, 352  
   Pfizer-Wyeth, 389, 469  
   Sanofi, Aventis acquisition, 379  
 Pharmaceutical innovation  
   BLAs, 21  
   definition of new drug, 21  
   generic drugs, 21  
   me-too drugs, 21  
   NMEs, 21  
 Pharmaceutical Research  
   and Manufacturers of America  
   (PhRMA), 26  
   Annual Report, R&D spending, 34  
   NMEs, percent of R&D spending, 31  
 pharmacy benefits management companies  
   Anthem, 215  
   CVS, 215  
   Express Scripts, 215  
   Prime Therapeutics, 215  
 Pharmasset, 208, 210, 219  
 phenformin, 263, 263f. 9.1, 270t. 9.1, 282–84,  
   291, 294, 299  
 phenobarbital, 119  
 Philadelphia chromosome, 312, 333  
   approval of Gleevec as treatment, 353  
   discovery, 334, 338  
 Philadelphia chromosome-positive chronic  
   myelogenous leukemia (CML), 63  
 Philadelphia, PA, 115  
 Philips, 167  
 Pittsburgh, PA, 485  
 Pixar, 463  
 polycystic ovary syndrome (PCOS), 263  
 Portland, Oregon, 95  
 Posner, Richard, 13  
 Praluent, 363, 387  
 Prasad, Vinay, 443  
 Pravachol, 103, 106  
 precision medicine, 301  
 Precision Medicine Initiative, 314  
 prediabetes, 263, 267, 296n. 101, 296n. 98, 295–98  
   treatment with metformin, 295  
 Presbyterian Hospital, Philadelphia, 338  
 Prescription Drug User Fee Act (PDUFA), 54  
 presenilin-1, 232, 236n. 37, 236n. 38  
 presenilin-2, 232  
 pricing, pharmaceuticals, 59  
   elasticity, 62  
   marginal value, 60  
   value distribution, 60  
 Pricing, pharmaceuticals  
   Lerner Index. *See* pricing, pharmaceuticals:  
   Markup pricing rule  
   price discrimination, 61  
   price discrimination, EU versus US, 411  
 Prime Therapeutics, 215  
 priority review status, 22  
 Procter & Gamble, 369, 377  
 Procysbi, 64  
 prorenin, 121  
 Proudfit, William, 167  
 Ptolemy, 518  
 Purcell, Robert, 193  
*Pythium ultimum*, 87  
 Questcor, 65n. 7  
 Raal, Frederick, 105  
 Rabbi Judah the Prince, 304

- Rabstein, Louise, 344  
 Radiological Society of North America, 169  
 Rahway, New Jersey, 92  
 ramipril, ACE inhibitor, 155  
 Ramipril, ACE inhibitor, 126  
 RAND Corporation, 225  
 ranibizumab, 398  
 Raptor, 64  
 Raspail, Francois-Vincent, 335  
 Rathery, Francis, 280  
 Reagan, Ronald  
   Alzheimer's disease, 254  
 Regeneron, 362, 463  
   Arcalyst, 375  
   Eylea, 375  
   Lucentis, 380  
   name origin, 374  
   Orphan Receptor Initiative, 374  
   Praluent, 387  
   Regeneron 5, 367, 392  
   Regeneron Genetics Center (RGC), 392  
   Taxotere, 379  
   TRAP technology, 375  
   VelociGene technology, 368, 382  
   VelociSuite technologies, 384  
   Zaltrap, 375  
 Reid, Donald, 171  
 Reinwein, Helmuth, 273  
 renin, 130  
 renin-angiotensin-aldosterone system (RAAS), 121  
 Rensselaer, New York, 381  
*Reports of Medical Cases*, 128  
 research and development (R&D)  
   1986 tax credit system, US, 33  
   cost estimates - cash versus capitalized, 32  
   costs, 29  
   expenses, US, 18  
   investment decision-making, 47  
   R&D dollars per drug, 37  
   rate of return, 30  
   return on investment (ROI), 30  
   revenues per R&D dollar, 37  
   small molecule, 25  
   tax benefits, 33  
 Rhea, Lawrence, 165  
 rheumatoid arthritis  
   cause, 52  
   drug development, 57  
 Ricardo, David, 38  
 Roberts, Tom, 347  
 Roche, 203–04, 208, 391  
 Rochester, NY, 100  
 Rockefeller University, 135, 201, 220, 342  
 Roosevelt, Eleanor, 119  
 Roosevelt, Franklin Delano (FDR), 119  
 Rosch, Josef, 170  
 Rosenberg, Nathan, 519  
 Rosenberg, Steven, 428–29  
 Rosenfeld, Philip J., 408  
 Roth, Bruce, 100  
 Roth, Martin, 230  
 Rothfield, Lawrence, 83  
 Roubin, Gary, 187  
 Rous, Peyton, 342  
 Rowley, Janet, 339, 354  
 Royal College of Surgeons, London, 137  
 Royal Society of England, 15, 508  
 Royal Victoria Hospital, Belfast, 281  
 Royston, Ivor, 487  
 Rubin, Harry, 342  
 Rutgers University  
   Institute for Microbiology, 17  
 Sadelain, Michel, 429, 436, 446  
 Salk Institute for Biological Studies, 478, 485, 487  
 San Diego, California  
   biotech cluster, 484  
 Sandoz  
   fluvastatin, 110  
 Sandoz Pharmaceuticals, 102, 350, 352  
 Sanford Burnham Institute, 485  
 Sanger, Fred, 457  
 Sankyo Research Laboratories, 85  
 Sanofi, 369, 379, 389, 394  
 Sanofi-Aventis, 276  
 Sawyers, Charles, 352  
 Scandinavian Simvastatin Survival Study (the '4S study'), 99  
 Schatz, Albert, 514  
   streptomycin. *See* streptomycin  
 Schering AG, 274  
 Schering-Kahlbaum AG, 274  
 Schering-Plough, 203–05  
 Schlumpf, Maria, 173  
 Schmid, Helmuth, 175  
 Schmidt, Warren, 211  
 Schonberg, Georg Albers, 92  
 Schumpeter, Joseph, 13  
 scientific method  
   definition, history, 163  
 Scolnick, Edward, 96

- Scott, Winfield, 475  
 Scripps Research Institute, 200, 478, 485  
 Seattle, Washington, 433  
 Seed, Brian, 426  
 Sefton, Batholemew, 344  
 Seitz, Walter, 282  
 Seldinger, Sven Ivar  
   Seldinger Technique, 167  
 Senning, Ake, 168, 177, 181  
 Séquard, Charles Edward Brown, 146  
 Sharp, Phillip  
   Nobel Prize, 1993, 484  
 Sharp, Phillip Allen, 477  
 Shenfield, Gillian, 262  
 Shirey, Earl, 167  
 Shleifer, Leonard (Len), 363  
 Shooter, Eric, 364  
 Siegenthaler, Walter, 181  
 Silva, Mauricio Rocha e, 136  
 Simpson, John, 187  
 simvastatin, 98  
 Sing, George, 369  
 Siperstein, Marvin D., 84  
 Skeggs, Leonard, 135, 148  
 Slamon, David, 406  
 Slater, Robert, 349  
 Sloan School of Management, MIT, 484  
 Slotta, K.H., 282  
 small molecule R&D, 25  
 Smith, Charles (Chuck), 139  
*Société de Biologie*, 128  
 Sofia, Michael, 210, 219  
 Sones, Frank Mason, 167, 179  
 Sovaldi, 58, 209  
 specialty drugs  
   ATC category, 23, 25  
 spotlight effect  
   definition, scientific community, 146  
 St Mary Abbots Hospital, London, 281  
 St Mary's Hospital Medical School,  
   London, 135  
 St. Jude Children's Research Hospital, 429  
 St. Mary's Hospital, San Francisco, 176, 182  
 Stahl, Neil, 375  
 Stanford University, 187, 477–78, 487  
 Starr, Chris  
   Raptor, 64  
 statins, 10, 18  
   Akira Endo, 82  
   chemical structures, 350  
   discovery, 75  
   health risks, rhabdomyolysis, 107  
   pricing, 63  
 Steinberg, Daniel, 95  
 Stephan, Paula, 515  
 Sterne, Jean, 262, 274, 277  
 sterol regulatory element binding process  
   (SREBP), 113  
 Stockholm, Sweden, 129  
 stomach ulcers  
   drug development, 57  
 streptomycin, 16–17  
 stroke, 120  
 sulfadiazine, 277  
 Sumitomo, 369  
 sunitinib, 312  
 Swiss National Science Foundation, 175  
 Symposium on Drugs Affecting Lipid  
   Metabolism, 6<sup>th</sup> Annual, 115  
 Synthalin, 274  
  
 T. Rowe Price Group, 394  
 Tacchini, Alberto C.  
   renin, 133  
 Talpaz, Moshe, 352  
 Tanret, Georges, 272  
 Tarrytown, New York, 371  
 tau hyperphosphorylation, 237f. 8.1, 243  
 tau hypothesis, 242, 244  
 Taxotere, 379  
 T-cells  
   use in cancer treatments, 421  
 Technivie, 213  
 Temin, Howard, 342  
   Nobel Prize 1966, 343  
 Teva, 369  
*Textbook of Human Physiology*  
   Robert Tigerstedt, 150  
 The National Center for Advancing  
   Translational Science (NCATS), 56  
 The Prescription Drug User Fee Act, 1992  
   (PDUFA), 54  
 Tigerstedt, Robert, 129, 146  
   Lifetime Achievement Award, 130  
   *Textbook of Human Physiology*, 150  
 Tijo, Joh Hin, 337  
 Titian, 506  
 TNF (tumor necrosis factor) drugs  
   pricing, 63  
 Todaro, George J., 343  
 Tohoku University Faculty of  
   Agriculture, 82

- Tokyo Metropolitan Institute for Neuroscience, 200  
 Tokyo Noko University, 93  
 Tokyo, Japan, 85  
 Trinity College, Dublin  
   University Chemical Laboratory, 283  
 Tschesche, R., 282  
 tuberculosis, 2  
 Tübingen, Germany, 228  
 Tuffier, Theodore, 164  
 Tufts Medical School, 477  
 Tufts University, 485  
 Turina, Marco, 175  
 Turner syndrome, 337  
   cause, 308  
 Twenty First Century Cures Act, US, 503  
 twin pillars of success  
   invention and commercialization, 183
- US Catheter and Instrument Company, 167  
 UK Prospective Diabetes Study (1977–1997), 286  
 Ullrich, Axel, 406  
 Ungar, Georges, 282  
 University College Hospital Medical School, London, 266  
 University Hospital, Zurich, 172  
 University of Aberdeen, 90  
 University of Breslau, 274, 282  
 University of Buenos Aires, 132  
 University of California, Berkeley, 514  
 University of California, Los Angeles, 346, 406  
 University of California, San Diego, 478, 485, 487  
 University of California, San Francisco, 343, 404, 426, 477–78  
 University of Catania Medical School, 404  
 University of Heidelberg, 171  
 University of Helsinki, 149  
 University of Lund, Sweden, 287  
 University of Michigan  
   Regional Conference on the Basic Mechanisms of Arterial Hypertension, 135  
 University of Munich, 228  
 University of Münster, 282  
 University of Newcastle, England, 230  
 University of Nottingham, 90  
 University of Oregon, 168, 170  
 University of Oregon Medical School, 168  
 University of Oxford, 113  
 University of Padua, Italy, 506  
 University of Pennsylvania, 417, 427, 429  
 University of Pennsylvania Medical School, 338  
 University of Rochester, 100  
 University of Strasbourg, 275  
 University of Texas, 336, 352  
 University of Texas Southwestern Medical Center, 96  
 University of Texas Southwestern Medical School, 84  
 University of Toronto, 275, 516  
 University of Zurich, 168  
 US Diabetes Prevention Program, 296  
 US major causes of death, 2  
 US standard of living, 1  
 US Vitamin Corp., New York City, 282
- vaccination, 15  
 Vagelos, P. Roy, 83, 109, 115, 364, 394, 396, 452  
   Merck & Co., 91  
 Valenzuela, David, 367  
 valley of death, 10, 54  
 van Etten, Richard A., 346  
 Vane, John, 137, 151, 157  
 variolation, 15  
 Varmus, Harold, 343  
 vascular endothelial growth factor (VEGF), 375–76  
 vascular retinopathy, 120  
 Vasella, Daniel, 349, 352  
 vasopressin, 123  
 Vertex, 68, 205  
 Vesalius, Andreas, 14  
   human anatomy, 505  
 Veterans Administration Hospital Cooperative Study Group on Antihypertensive Agents, 124  
 Virchow, Rudolf, 334  
 Volhard, Franz, 151  
 von Hanseman, Daniel Paul, 335  
 von Langenbeck, Bernhard, 334  
 von Leeuwenhoek, Anton, 15  
   discovery of bacteria, 507  
 von Mering, Josef, 275  
 von Recklinghausen, Friedrich Daniel, 305
- Waksman, Selman  
   discovery of streptomycin, 513  
   streptomycin. *See* streptomycin  
 Walker, I.C., 165

542

Wall Street, 32  
Walpole, Horace  
    serendipity, 458  
War on Cancer, 12, 340, 356, 493, 524  
Warner-Lambert, 100, 117  
Washington University, 92, 165, 364  
Washington, DC, 124, 485  
Watanabe, C.K., 271, 277  
Watson, Thomas, 455  
Weber, Max, 464  
Weiner, Richard, 404  
Weiss, Arthur, 426  
Weizmann Institute of Science, Rehovot, Israel,  
    345, 426  
Welch, Arnold, 139, 141, 157  
Wellauer, Josef, 172  
Werner, Emil, 283  
Whitehead, Emma, 417, 432, 445  
Wickersham, Peter, 215  
Wilde, Oscar, 314  
William Cook Europe, 178  
Williams, David, 177  
Wilson, Jean, 95  
Winslow, Ron, 103  
Witte, Owen, 345  
Witty, Andrew  
    GlaxoSmithKline, 64

*Index*

Wolfenden, Richard, 142  
Woodruff, H. Boyd  
    Merck, 91  
World Health Organization (WHO), 191  
    100 essential medicines, 398  
    Anatomical Therapeutic Chemical (ATC)  
        Classification System code, 22, 25  
    definitions of genetics and genomics, 301  
    model list of essential medicines, 209  
Wren, Sir Christopher, 508  
Wyeth, 469  
  
Xeljanz, 67  
  
Yale University, 153, 272  
Yamamoto, Akira, 89, 110, 117  
Yancopoulos, George, 364  
*Yellow Emperor's Classic of Internal  
    Medicine*, 127  
  
Zaltrap, 375  
Zeitler, Eberhard, 172  
Zerhouni, Elias, 395  
Zika, 195, 387  
Zimmermann, Jurg, 349, 354–55  
Zocor (simvastatin), 103, 106–07  
Zurich, Switzerland, 172